Galapagos NV (GLPG)
NASDAQ: GLPG · Real-Time Price · USD
28.01
-0.06 (-0.21%)
At close: Jun 27, 2025, 4:00 PM
27.98
-0.03 (-0.11%)
After-hours: Jun 27, 2025, 4:32 PM EDT
Galapagos NV Revenue
Galapagos NV had revenue of 74.98M EUR in the quarter ending March 31, 2025, with 20.09% growth. This brings the company's revenue in the last twelve months to 288.19M, up 18.31% year-over-year. In the year 2024, Galapagos NV had annual revenue of 275.65M with 14.99% growth.
Revenue (ttm)
288.19M EUR
Revenue Growth
+18.31%
P/S Ratio
5.97
Revenue / Employee
409,366 EUR
Employees
704
Market Cap
1.86B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 275.65M | 35.93M | 14.99% |
Dec 31, 2023 | 239.72M | -1.53M | -0.63% |
Dec 31, 2022 | 241.25M | 6.87M | 2.93% |
Dec 31, 2021 | 234.38M | -243.67M | -50.97% |
Dec 31, 2020 | 478.05M | -356.85M | -42.74% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
GLPG News
- 5 days ago - Galapagos Appoints Aaron Cox as Chief Financial Officer - GlobeNewsWire
- 10 days ago - Galapagos Presented New Data at ICML 2025 From Cohort 3 of ATALANTA-1 in Relapsed/Refractory Indolent NHL Patients, Demonstrating High Complete Response and MRD Negativity Rates With CAR-T Candidate GLPG5101 - GlobeNewsWire
- 16 days ago - Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL - GlobeNewsWire
- 4 weeks ago - Galapagos Creates New Subscription Right Plan - GlobeNewsWire
- 6 weeks ago - Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes - GlobeNewsWire
- 2 months ago - Galapagos: Targeting High Unmet Medical Need Of MCL Focus With GLPG5101 - Seeking Alpha
- 2 months ago - Galapagos NV (GLPG) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Galapagos Reports First Quarter 2025 Financial Results, Recent Business Highlights and Near-Term Catalysts - GlobeNewsWire